Findings

What do systematic reviews say?

106 questions · 106 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 10 · 9.4%GRADE not reported 0 · 0%Very low 18 · 17%Low 37 · 34.9%Moderate 39 · 36.8%High 2 · 1.9%

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher biopsy‐proven acute rejection compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 1.7 [1.32, 2.19]
15 studies · 3309 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

CMV infection · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) leads to lower CMV infection compared with calcineurin inhibitors (CNI): main outcomes (high certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.43 [0.29, 0.63]
13 studies · 2026 participants
High

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Wound complications · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher adverse wound outcomes: all complications compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 2.56 [1.94, 3.36]
12 studies · 1679 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

All malignancies · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in all malignancies compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 0.86 [0.5, 1.48]
10 studies · 2584 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): main outcomes

Number needing to change treatment · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher number needing to change treatment compared with calcineurin inhibitors (CNI): main outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 2.42 [1.88, 3.11]
14 studies · 3148 participants
Moderate

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Outcomes (up to 2 years for secondary outcomes) · primary immunosuppression in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found